The SMC approves Cimzia (Certolizumab Pegol) for the treatment of psoriasis in adults in Scotland.
The Scottish Medicines Consortium (SMC) has today published its decision to recommend Cimzia (Certolizumab Pegol) as a treatment for adults with moderate to severe plaque psoriasis in Scotland.
Cimzia may be prescribed to adult patients who have not responded to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), or who cannot take these medications.
How does Cimzia work?
Cimzia is a biologic treatment which blocks tumour necrosis factor-alpha (TNF alpha) a chemical ‘messenger’ in the immune system that signals other cells to cause inflammation.
There is too much TNF alpha in the skin of people with psoriasis, which causes inflammation and can lead to tissue damage. TNF alpha can also lead to increased activity of the immune system by switching on certain white blood cells in the body, called T Cells. Once T cells become overactive they can trigger inflammation and other immune responses, encouraging the development of psoriasis.
Cimzia helps lower the amount of TNF alpha to more normal levels, and switches off the inflammatory cycle of psoriasis. This leads to improvement in symptoms for many people who take it.
How is Cimzia taken?
Cimzia is taken by injection at a dose of 200mg every 2 weeks (after the 'loading dose' of two injections of 400mg in each of weeks 0,2 and 4).
You can read more information about Cimzia, as well as its dosing regime and possible side effects by downloading our information sheet.